Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Preoperative Chemoradiotherapy Plus Avelumab in Patients With Locally Advanced Rectal Cancer
2017-003582-10Phase 2Completed
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in rectal cancer, sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Pathologic Complete Response (pCR) Rate. Started Jun 2021; status: completed.
02
Drugs
avelumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2017-003582-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003582-10.